Building on this, CV9202 (BI 1361849), encoding additional TAAs (e.g., NY-ESO-1, MAGE-C1), was developed and evaluated in a Phase Ib trial in combination with localized radiotherapy in patients with advanced NSCLC and stable disease. The gene discussed is MAGEC1; the disease is non-small cell lung carcinoma.